TORONTO, Jan. 21, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated October 17, 2019 (the “Base Shelf Prospectus”) in the United States and Canada relating […]
TORONTO, Jan. 22, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of US$11.65 per Common Share (the “Offering Price”).
TORONTO, Jan. 27, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”) at a price of US$11.65 per Common Share. The underwriters elected to exercise the over-allotment […]
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that it has retired its $12.5 […]
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”)
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private placement (the “Private Placement”) for aggregate gross proceeds of […]
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2023, and provided an update on the progress it […]
TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the public of US$7.50 per Common Share, led by healthcare focused institutional investors. Gross proceeds […]
TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company intends to file a preliminary prospectus supplement (the […]